CancerDrs

Head and Neck Cancer clinical trials in Montana

7 actively recruiting head and neck cancer trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Saint Vincent Healthcare — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Saint James Community Hospital and Cancer Treatment Center — Butte, Montana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Montana:
  • Intermountain Health Cancer Centers of Montana — Billings, Montana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Great Falls Clinic — Great Falls, Montana
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana:
  • Massive Bio SYNERGY-AI site — Billings, Montana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10